| HOME >> MEDICINE >> TECHNOLOGY |
- Not Intended for Journalists in the UK or Ireland - New Findings From ARTEMIS and TITAN Studies Demonstrate Growth of the
Tibotec Virology Franchise
GLASGOW, Scotland, Nov. 12 /PRNewswire/ -- New data on PREZISTA(R) (darunavir), a protease inhibitor from Tibotec, will be presented at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, U.K., from 09-13 November 2008. The company also presented new data on PREZISTA(R) at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C., from 25-28 October 2008. These presentations follow key regulatory approvals and decisions for PREZISTA(R) and INTELENCE(TM) (etravirine), a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). The company continues to research various compounds in hepatitis C, tuberculosis and HIV.
"The Tibotec data being presented at HIV9 culminate an exciting three
months for the company and for the entire HIV community," said Roger
Pomerantz, President, Tibotec Research & Development. "The data we've
amassed and the regulatory milestones we've achieved this year are signs of
our dedication to finding innovative ways to meet the needs of people with
HIV."
Recent Regulatory Milestones for Tibotec in HIV
- 28 August 2008 - The European Commission approved etravirine, in
combination with a boosted protease inhibitor and other antiretroviral
medicinal products, for the treatment of human immunodeficiency virus
type 1 (HIV-1) infection in antiretroviral treatment-experienced adult
patients.
- 21 October 2008 - The U.S. FDA granted traditional approval to
darunavir, coadministered with low dose ritonavir, for twice-daily use
in treatment-experienced adult patients, as well as an expanded
indication for once-daily dosing as part of HIV combination therapy in
treatment-na
'/>"/>
| SOURCE Tibotec Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved |